Milica Mitrevski
Overview
Explore the profile of Milica Mitrevski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schutz K, Alecsandru D, Grimbacher B, Haddock J, Bruining A, Driessen G, et al.
J Clin Immunol
. 2019 Mar;
39(2):225-227.
PMID: 30905051
In the original version of this article unfortunately two authors were missing: Dr. Jürgen Weidemann and Dr. Daniel Berthold. The correct list of authors is presented above.
2.
Schutz K, Alecsandru D, Grimbacher B, Haddock J, Bruining A, Driessen G, et al.
J Clin Immunol
. 2018 Dec;
39(1):45-54.
PMID: 30547383
Studies of chest computed tomography (CT) in patients with primary antibody deficiency syndromes (ADS) suggest a broad range of bronchial pathology. However, there are as yet no multicentre studies to...
3.
Camponeschi A, Todi L, Cristofoletti C, Lazzeri C, Carbonari M, Mitrevski M, et al.
Immunol Lett
. 2018 Mar;
198:7-11.
PMID: 29601939
The transcription factor DEC1/STRA13 (also known as BHLHE40 and SHARP2) is involved in a number of processes including inhibition of cell proliferation and delay of cell cycle, and is a...
4.
Quinti I, Mitrevski M
Front Immunol
. 2017 Jul;
8:697.
PMID: 28670314
Intravenous immunoglobulin administered at replacement dosages modulates innate and adaptive immune cells in primary antibody deficiencies (PAD) in a different manner to what observed when high dosages are used or...
5.
Del Padre M, Todi L, Mitrevski M, Marrapodi R, Colantuono S, Fiorilli M, et al.
Blood
. 2017 May;
130(1):35-38.
PMID: 28507081
Hepatitis C virus (HCV) causes mixed cryoglobulinemia (MC) by driving clonal expansion of IgMCD27 B cells. These cells display both the features of anergy induced by continual engagement of the...
6.
Colantuono S, Mitrevski M, Yang B, Tola J, Carlesimo M, De Sanctis G, et al.
Clin Rheumatol
. 2017 Jan;
36(3):617-623.
PMID: 28111716
This study aims to evaluate the efficacy and safety of repeated treatments with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis. Thirty-seven patients with mixed cryoglobulinemia vasculitis refractory to standard of...
7.
Gragnani L, Visentini M, Fognani E, Urraro T, De Santis A, Petraccia L, et al.
Hepatology
. 2016 Aug;
64(5):1473-1482.
PMID: 27483451
Conclusion: Interferon-free, guideline-tailored therapy with direct-acting antivirals is highly effective and safe for HCV-associated MC patients; the overall 100% rate of clinical response of vasculitis, on an intention-to-treat basis, opens...
8.
Visentini M, Pascolini S, Mitrevski M, Marrapodi R, Del Padre M, Todi L, et al.
Clin Exp Rheumatol
. 2016 Jan;
34(3 Suppl 97):S28-32.
PMID: 26811981
Objectives: To investigate the expression of a VH1-69-encoded idiotype, and the phenotypic and functional features of monoclonal B-cells from patients with type II mixed cryoglobulinaemia (MC) secondary to chronic hepatitis...
9.
Visentini M, Tinelli C, Colantuono S, Monti M, Ludovisi S, Gragnani L, et al.
Autoimmun Rev
. 2015 Jun;
14(10):889-96.
PMID: 26031898
Objective: To evaluate whether rituximab at a low dose of 250 mg/m(2) × 2 may be as effective as at higher dosages, most commonly 375 mg/m(2)×4, used in previous studies...
10.
Mitrevski M, Marrapodi R, Camponeschi A, Cavaliere F, Lazzeri C, Todi L, et al.
Front Immunol
. 2015 Feb;
6:4.
PMID: 25657650
Intravenous immunoglobulin (IVIG) is used as replacement therapy in patients with antibody deficiencies and at higher dosages in immune-mediated disorders. Although different mechanisms have been described in vitro, the in...